Drugmaker Acknowledges Overcharging 340B Entities

by Admin | September 15, 2015 2:09 pm

September 15, 2015—Heritage Pharmaceuticals, a U.S.-based generic-drug manufacturer owned by the Indian drugmaker Emcure, has posted a notice on the 340B drug pricing program website[1] stating it “recently determined that 340B pricing to participating 340B covered entities was not extended on purchases of its products made between April 18, 2008 and December 31, 2014.”  

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[2].    Already registered? Click here to login[3]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Endnotes:
  1. a notice on the 340B drug pricing program website: http://www.hrsa.gov/opa/programrequirements/manufacturerletters/2015/heritageletter.pdf
  2. Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
  3. Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2015/09/drugmaker-acknowledges-overcharging-340b-entities/

Copyright ©2026 340binformed.org unless otherwise noted.